Improving the safety and bioavailability of anti-aging treatments

Background

While estradiol has proven benefits for reversing signs of skin aging, traditional systemic delivery methods pose significant risks, including an increased likelihood of breast cancer, deep vein thrombosis (DVT) and stroke. Recognizing the need for a safer alternative, Professor Tarl Prow and Dr Miko Yamada co-founded Estrenue Pty Ltd to commercialize a novel delivery system, Elongated Microparticles (EMP), to localize the effects of estradiol directly to the skin’s dermal layer, thereby avoiding systemic side effects.

‍

Objective

To develop and commercialize EMP for the topical treatment delivery of estradiol safely and effectively to aging skin without increasing blood estrogen levels, addressing a critical unmet need in dermatology and skincare.

‍

Approach

Leveraging Prof Prow and Dr Yamada’s deep expertise in commercialization and clinical development, Estrenue Pty Ltd has:

• designed a formulation strategy utilizing EMP to deliver estradiol precisely to the dermal layer
• led clinical validation efforts to ensure efficacy and safety while addressing regulatory compliance challenges
• overseen product development and commercialization, aligning the innovation with market needs in dermatology and cosmetic applications.

Results

• Successful development of a novel, non-invasive micro- and nanoscale technology delivery system, EMP, capable of delivering estradiol directly to the skin’s dermal layer.
• Demonstration that the product effectively restores aged skin without increasing systemic estrogen levels, mitigating risks of breast cancer, DVT and stroke.
• Translation of ground-breaking laboratory research into a commercially viable product for the dermatology and skincare markets.

Key takeaways

• Our leadership and expertise in clinical development and commercialization were instrumental in founding Estrenue Pty Ltd and bringing its novel product to market.
• EMP technology represents a significant breakthrough in topical drug delivery, combining safety and efficacy for aging skin treatments.
• The project highlights our consultancy’s ability to turn innovative science into real-world solutions with global market potential.